Thursday, July 20, 2023
Caris Life Sciences®, a prominent molecular science and technology company dedicated to revolutionizing healthcare, has announced that University Hospitals (UH) Seidman Cancer Center is now part of the Caris Precision Oncology Alliance™ (POA). The POA is an expanding network of leading cancer centers and research consortia globally, collaborating to advance precision oncology and biomarker-driven research. Its members work together to establish and optimize standards of care for molecular testing, with the goal of improving clinical outcomes for cancer patients. By leveraging Caris' advanced AI bioinformatics and machine learning capabilities across their extensive clinico-genomic database, POA members engage in innovative research to drive progress in cancer care.
UH Seidman Cancer Center, serving as Northeast Ohio's only freestanding cancer hospital, is deeply committed to cancer prevention, diagnosis, treatment, and pioneering research through clinical trials. As part of the National Cancer Institute (NCI)-designated Case Comprehensive Cancer Center at Case Western Reserve University, UH Seidman Cancer Center encompasses 14 cancer-specific teams focused on developing integrated care plans tailored to meet the unique needs of each patient.
Dr. Theodoros Teknos, President and Scientific Director of UH Seidman Cancer Center, expressed enthusiasm for the collaborative potential of uniting AI technology with the brightest oncologic minds and a vast cancer profiling database. He emphasized the institution's dedication to becoming a leading cancer research center by joining forces with the Caris Precision Oncology Alliance.
Chadi Nabhan, M.D., MBA, FACP, Chairman of the POA, warmly welcomed UH Seidman Cancer Center to the growing Caris Precision Oncology Alliance network. He highlighted the shared vision of the researchers, clinicians, and leaders at Seidman Cancer Center, all working towards improving cancer patient outcomes through cutting-edge precision oncology research.
The Caris Precision Oncology Alliance, with 87 members including cancer centers, academic institutions, research consortia, and healthcare systems, offers early access to Caris' extensive database and AI platform. This empowers member institutions to establish evidence-based standards for cancer profiling and molecular testing in oncology, leading to prioritized therapeutic options and enhanced clinical trial opportunities for patients. Additionally, POA members gain access to the industry's most comprehensive clinico-genomic database, housing matched molecular and clinical outcomes data from hundreds of thousands of cancer patients, providing invaluable insights for their research endeavors.